18889881171
Kalkine 0
countryflagUS

Assertio Therapeutics Inc

Healthcare US ASRT

0.7USD
0.03(5.14%)

Last update at 2025-05-19T19:01:00Z

Day Range

0.670.70
LowHigh

52 Week Range

0.736.56
LowHigh

Fundamentals

  • Previous Close 0.67
  • Market Cap95.12M
  • Volume151946
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA34.95M
  • Revenue TTM142.05M
  • Revenue Per Share TTM1.73
  • Gross Profit TTM 138.29M
  • Diluted EPS TTM-4.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 31.17M -0.55300M -45.51300M -222.48400M 37.98M
Minority interest - - - - -
Net income 109.62M -1.28100M -28.14400M -217.20100M 36.91M
Selling general administrative 46.79M 56.55M 104.32M 108.87M 119.22M
Selling and marketing expenses - - - - -
Gross profit 137.49M 95.18M 86.40M 220.00M 293.29M
Reconciled depreciation 33.40M 29.08M 26.43M 102.95M 106.43M
Ebit 57.81M 9.42M -46.91700M 3.20M 65.46M
Ebitda 91.21M 39.83M -25.35900M 104.97M 167.23M
Depreciation and amortization 33.40M 30.41M 21.56M 101.77M 101.77M
Non operating income net other - - - 30.33M 1.20M
Operating income 57.81M 9.42M -46.91700M 3.20M 43.66M
Other operating expenses 98.14M 100.50M 153.19M 230.25M 247.51M
Interest expense 7.96M 10.22M 15.93M 58.39M 68.88M
Tax provision -78.45900M 0.73M -17.36900M -5.28300M 1.07M
Interest income - - - 54.44M 1.20M
Net interest income -7.96100M -10.22000M -15.92600M -58.38900M -67.68400M
Extraordinary items - - - - -
Non recurring - - - 193.68M -41.39900M
Other items - - - - -
Income tax expense -78.45900M 0.73M -17.36900M -5.28300M 1.07M
Total revenue 156.23M 111.01M 106.28M 229.50M 311.77M
Total operating expenses 79.39M 84.67M 133.32M 220.75M 229.03M
Cost of revenue 18.75M 15.83M 19.87M 9.51M 18.48M
Total other income expense net -26.64800M -9.97700M 1.40M -225.68500M 41.40M
Discontinued operations - - - - -
Net income from continuing ops 109.62M -1.28100M -28.14400M -217.18400M 36.91M
Net income applicable to common shares 109.62M -1.28100M -28.14400M -217.20100M 36.91M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 286.42M 413.91M 326.55M 303.27M 527.17M
Intangible assets 111.33M 198.00M 216.05M 200.08M 400.54M
Earning assets - - - - -
Other current assets 12.27M 8.27M 14.84M 17.41M 15.69M
Total liab 148.42M 188.19M 224.13M 247.76M 469.21M
Total stockholder equity 138.00M 225.72M 102.41M 55.51M 57.96M
Deferred long term liab - - - - -
Other current liab 79.08M 88.86M 48.80M 9.46M 2.09M
Common stock 0.00900M 0.00500M 0.00400M 0.01M 0.00800M
Capital stock 0.00900M 0.00500M 0.00400M 0.01M 0.00800M
Retained earnings -651.54300M -319.60100M -429.22600M -427.94500M -399.80100M
Other liab - 26.47M 27.80M 40.10M 8.58M
Good will - - - - -
Other assets 0.00000M 82.51M 5.47M 206.58M 3.35M
Cash 73.44M 64.94M 36.81M 20.79M 42.11M
Cash and equivalents - - - - -
Total current liabilities 93.44M 95.32M 135.02M 132.69M 184.55M
Current deferred revenue - - 67.36M 96.48M 86.27M
Net debt -32.52900M 1.93M 36.68M 63.32M 309.15M
Short term debt 0.93M 0.47M 12.17M 11.94M 80.00M
Short long term debt - 0.47M 12.17M 11.94M 80.00M
Short long term debt total 40.91M 66.87M 73.49M 84.10M 351.26M
Other stockholder equity 789.54M 545.32M 531.64M 483.45M 457.75M
Property plant equipment - 0.88M 1.53M 4.78M 3.50M
Total current assets 171.06M 132.26M 103.50M 94.25M 103.95M
Long term investments - 0.27M 1.58M 1.58M 13.06M
Net tangible assets - 27.73M -113.64000M -144.56800M -342.57700M
Short term investments - - - 1.58M -
Net receivables 47.66M 45.36M 44.36M 44.35M 42.74M
Long term debt 38.21M 66.40M 61.32M 72.16M 271.26M
Inventory 37.69M 13.70M 7.49M 11.71M 3.41M
Accounts payable 13.44M 5.99M 6.68M 14.81M 16.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -11.87000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -399.80100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.99M 2.44M 5.47M 4.92M 6.12M
Deferred long term asset charges - - - - -
Non current assets total 115.36M 281.65M 223.05M 209.02M 423.22M
Capital lease obligations 1.47M - - - 6.91M
Long term debt total - - - - 271.26M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -42.67300M -18.52500M 512.80M -1.48100M -1.80000M
Change to liabilities -10.20800M -28.69900M -28.56900M -18.71000M -35.31200M
Total cashflows from investing activities -42.67300M -18.52500M 512.80M -1.48100M -7.08200M
Net borrowings -0.75000M -9.83500M -464.25600M -154.26800M -82.50000M
Total cash from financing activities -7.79400M 29.03M -468.55000M -157.83600M -81.35000M
Change to operating activities 4.78M -7.37300M -26.17900M 20.68M -117.78100M
Net income 109.62M -1.28100M -28.14400M -217.20100M 36.91M
Change in cash 28.13M 16.02M -21.32100M -68.84200M -15.93500M
Begin period cash flow 36.81M 20.79M 42.11M 110.95M 126.88M
End period cash flow 64.94M 36.81M 20.79M 42.11M 110.95M
Total cash from operating activities 78.60M 5.52M -65.57200M 90.47M 72.50M
Issuance of capital stock 7.02M 44.86M 0.09M 0.25M 2.02M
Depreciation 33.40M 29.08M 26.43M 102.95M 106.43M
Other cashflows from investing activities - - - - 0.23M
Dividends paid - -0.19300M - - -
Change to inventory -6.59300M 4.27M -0.29100M -0.31600M 9.05M
Change to account receivables -0.99600M -0.01100M 19.80M -5.53300M 35.27M
Sale purchase of stock -0.87200M -0.41800M -0.86600M -0.57000M -0.68600M
Other cashflows from financing activities 56.81M -5.38900M -13.51600M -4.26800M -0.18400M
Change to netincome -51.71300M 8.83M -25.32700M 177.98M 14.48M
Capital expenditures 0.27M 0.05M 0.01000M 1.48M 5.51M
Change receivables - - - -5.53300M 35.27M
Cash flows other operating - - - 27.54M -116.20500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -68.84200M -15.93500M
Change in working capital -13.01400M -31.29300M -44.21200M -0.60600M -107.19800M
Stock based compensation 7.50M 3.54M 10.92M 10.60M 12.59M
Other non cash items 21.46M 4.11M -22.14700M 200.51M 22.51M
Free cash flow 78.32M 5.47M -65.58200M 88.99M 66.99M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASRT
Assertio Therapeutics Inc		 0.03 5.14% 0.70 - 12.00 0.54 0.60 0.32 -0.2185
ZTS
Zoetis Inc		 0.82 0.50% 163.86 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.15 0.58% 25.93 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.05 0.80% 130.20 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.09 0.64% 14.20 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Therapeutics Inc

100 South Saunders Road, Lake Forest, IL, United States, 60045

Key Executives

Name Title Year Born
Mr. Daniel A. Peisert Pres, CEO & Director 1975
Mr. Paul Schwichtenberg Sr. VP & CFO 1971
Mr. Ajay Patel Sr. VP & Chief Accounting Officer 1984
Mr. Bill Iskos Sr. VP of Operations NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Technical Operations NA
Mr. Sam Schlessinger Sr. VP & Gen. Counsel NA
Mr. Jeff Christensen Sr. VP of Commercial NA
Ms. Heather L. Mason Interim CEO & Director 1960
Mr. Ajay Patel Senior VP & CFO 1985
Mr. Paul Schwichtenberg Senior Vice President & Chief Commercial Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.